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ABSTRACT  
 
Alteration in microRNAs (miRNAs) expression is a frequent finding in human cancers. In 
particular, global miRNAs down-regulation is a hallmark of malignant transformation through the 
mediation of Drosha and Dicer two key enzymes of global miRNAs processing. In the present 
report,. weHere we showed that the miR-128-3p, which is up-regulated in lung cancer tissues, has 
targeted two key enzymes of global miRNA processing, such as Drosha and Dicer as the main 
modulation targets. allowing the  This led to a global down-regulation of miRNA expression. We 
observed that the global downregulation induced by Such miR-128-3p -mediated effect contributed 
to the tumorigenic properties to the lung cancer cells. In particular miR-128-3p-mediated miRNAs 
dowregulation contributed to aberrant SNAIL and ZEB1 expression thereby promoting the 
epithelial-to-mesenchymal transition (EMT) program. Moreover, Drosha resulted to be implicated 
in the control of migratory phenotype as its expression counteracted miR-128-3p functional effects. 
Our study provides mechanistic insights into the function of miR-128-3p as a key regulator of the 
malignant phenotype of lung cancer cells. This also enforces the remarkable impact of Drosha and 
Dicer alteration in cancer, and in particular it highlights a role for Drosha in NSCLC cells 
migration. 
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Introduction  
 
MicroRNAs (miRNAs) are a class of non-coding RNAs regulating gene expression at the post-
transcriptional level. MiRNAs are transcribed by RNA polymerase II as primary miRNA (pri-
miRNA) and then processed into mature double-stranded miRNA by two major enzymes, Drosha 
and Dicer, which belong to the class of RNase III endonucleases. Mature miRNAs, through the 
RISC complex, can interact with the 3’ untranslated region (UTR) of mRNA targets, causing 
translational repression or mRNA deadenylation, depending on affinity of the miRNA to its mRNA 
target (1).  
MiRNAs are fine tuners of many biological processes, due to the multiplicity of mRNA targets for 
each miRNA (2). Altered miRNA biosynthesis has been associated with the occurrence of several 
diseases, among which cancer (3). In detail, deregulation of miRNAs expression was shown to 
promote cell proliferation, metastasis and chemoresistance (3). A large body of evidences suggests 
that a global reduction of miRNAs is a prevalent feature of human cancers (4-7). Deregulation of 
key components of the mRNA machinery can impinge on the global miRNAs down-regulation 
observed in cancer tissues (4,8). This is strongly supported by clinical correlative observations, 
which suggest prognostic value for altered levels of miRNA processors (9-12). In detail, Drosha and 
Dicer abrogation in cancer was ascribed to occurrence of somatic missense mutations, or deletions, 
or to transcriptional repression at the promoter level (13-15). More recently, evidences emerged 
pointing to a miRNA-mediated post-transcriptional modulation of Dicer by some miRNAs resulting 
into oncogenic features (16-18). 
MiR-128-3p is an intronic miRNA, that can be encoded both by miR-128-1 gene, located on human 
chromosome 2q21.3 into R3HDM1 gene, and by miR-128-2 gene, located on chromosome 3p22.3 
into ARPP-21 gene. Altered expression of miR-128 gene was reported in several types of human 
cancers, implying an important role in tumorigenesis (19). Its functions range from pro-tumorigenic 
to tumor suppressive, depending on the tissue analysed. In line with this, we have demonstrated that 
miR-128-3p is induced by mutant p53, contributing to mutant-p53-mediated chemoresistance in 
non-small-cell lung cancer (NSCLC), indicating an oncogenic role of miR-128-3p in lung cancer 
(20). 
In this study we demonstrated a direct binding and inhibitory effect of miR-128-3p on Drosha and 
Dicer 3’UTRs, causing a global down-regulation of miRNAs expression in NSCLC cells. Ectopic 
expression of the miR-128-3p reduced the levels of miRNAs targeting key EMT factors. This, 
ultimately, stimulated the invasive properties of the transfected cells. Moreover, reintroduction of 
Drosha in such a cellular context, determined a reversion of the migratory phenotype, suggesting a 
significant role of Drosha in the control of lung cancer cells migration.  
Collectively, these findings suggest that miR-128-3p-mediated ablation of Drosha and Dicer 
expression might contribute to the acquisition of a malignant phenotype of lung cancer cells by 
indirectly altering the levels of multiple effector miRNAs. 
 
Materials and methods 
 
Cell cultures and treatments  
Human cell lines H1299 and A459 were grown in RPMI medium (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% (v/v) FBS; all cell lines were grown at 37 °C in a balanced air humidified 
incubator with 5% CO2. All fresh cell lines were purchased from ATCC that has authenticated them 
by STR genotyping with Promega PowerPlex® 1.2 system and the Applied Biosystems Genotyper 
2.0 software for analysis of the amplicons. The cells were maintained in culture no more than six 
passages. All the cell lines have been tested by PCR/IF for Mycoplasma presence. 
  
 
Plasmids and transfections 
For mature miR-128-3p expression, we used mirVana™ miRNA Mimic Negative Control #1 
(Ambion) or hsa-miR-128-3p mirVana™ miRNA Mimic (Ambion) at final concentration of 5nM. 
For miR-128-3p depletion we used mirVana™ miRNA Inhibitor Negative Control #1 or hsa-miR-
128-3p mirVana™ miRNA Inhibitor (Ambion) at final concentration of 10nM. miR-128-3p 
expression was also abrogated using a lentiviral vector named TWEEN 3’-UTR (decoy vector), 
enclosing a multicloning site in the 3’-UTR of an GFP reporter gene, where we inserted two 
antisense sequences for miR-128-3p (decoy-miR-128-3p vector). H1299 and A459 cells were 
transfected using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s 
instructions. For Luciferase assay H1299 cells were co-transfected in 24-well dishes using 
Lipofectamine 2000 (Invitrogen) with 100ng of DROSHA-3’-UTR (wt and mutant)-Luciferase 
vectors (psiCHECK-2, Promega), 100ng of poli II vector and 20nM mirVana™ miRNA Mimic 
Negative Control #1 (Ambion) or hsa-miR-128-3p mirVana™ miRNA Mimic (Ambion). 
Moreover, H1299 cells were co-transfected in 24-well dishes using Lipofectamine 2000 
(Invitrogen) with 300ng of DICER-3’-UTR-(wt and mutant)-Luciferase vectors (a kind gift of Dr. 
Stefano Piccolo), and 20nM mirVana™ miRNA Mimic Negative Control #1 (Ambion) or hsa-miR-
128-3p mirVana™ miRNA Mimic (Ambion). 30ng of the transfection control Renilla vector 
(phRLTK, Promega) was used to normalize the firefly luciferase. Cells were harvested 48 hours 
post transfection and luciferase activities were analyzed by the dual-luciferase reporter assay system 
(Promega, Madison, WI) in the GloMax 96 Microplate Luminometer (Promega). Each sample was 
transfected in duplicate. Each experiment was repeated in triplicate. Drosha and Dicer mutants were 
made with the QuikChange site-directed mutagenesis kit (Stratagene) using the following primers: 
- DROSHA mut a40c_ t42g 
FW 5'-CATGCAAGTGTGGAGTATTTACTTGCTCAGTACAGGTGACTGTTGTCTATTG-3' 
RV 5'-CAATAGACAACAGTCACCTGTACTGAGCAAGTAAATACTCCACACTTGCATG -3' 
- DICER mut del 640-642  
FW 5'-TGTCTTTTCTTTCCACGTTATATGTAAGGTGATGTTCCCG-3' 
RV 5'-CGGGAACATCACCTTACATATAACGTGGAAAGAAAAGACA -3' 
For siRNA experiments, H1299 and A459 were transfected with siSCR (5’-
CUAUAACGGCGCUCGAUAU-3’), as a control or siDROSHA (5’-
AACGAGUAGGCUUCGUGACUU-3’)  at 0.1uM for 48 or 72 hours.  
For rescue experiments, H1299 cells were cotransfected with 500 ng of pcDNA3 (EV) or pcDNA3-
DROSHA expression plasmid and 5nM of hsa-miR-128-3p mirVana™ miRNA Mimic (Ambion) at 
the indicate time points.  
 
RNA extraction, labelling and microarray hybridization.  
RNA from FFPE samples was extracted using the miRneasy FFPE kit (QIAGEN) following the 
manufacturer’s instructions. The concentration and purity of total RNA were assessed using a 
Nanodrop TM 1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). Total 
RNA (100ng) was labelled and hybridized to Human miRNA Microarray Rel 14 V2 (Agilent). 
Scanning and image analysis were performed using the Agilent DNA Microarray Scanner (P/N 
G2565BA) equipped with extended dynamic range (XDR) software according to the Agilent 
miRNA Microarray System with miRNA Complete Labeling and Hyb Kit Protocol manual. Feature 
Extraction Software (Version 10.5) was used for data extraction from raw microarray image files 
using the miRNA_105_Dec08 FE protocol.  
 
Total RNA extraction from cells and reverse transcriptase.  
Total RNA was extracted using the TRIZOL Reagents (GIBCO). One microgram of total RNA was 
reverse-transcribed at 37°C for 60 minutes in the presence of random hexamers and Moloney 
murine leukemia virus reverse transcriptase (Invitrogen). PCR analyses were carried out using 
oligonucleotides specific for the genes listed in Supplementary Table S3. Gene expressions were 
measured by real-time PCR using the Syber Green assay (Applied Biosystems, Carlsbad, CA, USA) 
on a StepOne instrument (Applied Biosystems). 
Small amount of RNA (40ng) was reverse-transcribed using the TaqMan microRNA Reverse 
Transcription Kit (Applied Biosystem) and Real time-PCR of miRNA expression was carried out in 
a final volume of 10ul using ABI Prism 7000 Sequence Detection System (Applied Biosystems). 
The PCR Reactions were initiated with a 10 minutes incubation at 95°C followed by 40 cycles of 
95°C for 15 seconds and 60°C for 60 seconds. qRT-PCR quantification of miRNA expression was 
performed using TaqMan MicroRNA® Assays (Applied Biosystems) according to the 
manufacturer's protocol. RNU19 and RNU48 were used as endogenous control to normalize 
miRNA expression. All reactions were performed in duplicate.  
 
Lysate preparation and immunoblotting analysis. 
Cells were lysed in buffer with 50mM Tris-HCl pH 8, with 1% NP-40 (Igepal AC-630) 150mM 
NaCl, 5mM EDTA and fresh protease inhibitors. Extracts were sonicated for 10 seconds and 
centrifuged at 12000 ×rpm for 10 minutes to remove cell debris. Protein concentrations were 
determined by colorimetric assay (Bio-Rad). Western blotting was performed using the following 
primary antibodies: mouse monoclonal anti-Gapdh (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), rabbit monoclonal anti-Drosha (Cell Signaling), rabbit polyclonal anti-Dicer (Santa Cruz 
Biotechnology), rabbit monoclonal anti-Zeb1 (Cell Signaling), rabbit monoclonal anti-Snail (Cell 
Signaling) and mouse monoclonal anti B-actin (Santa Cruz Biotechnology sc-81178). Secondary 
antibodies used were goat anti-mouse and goat anti-rabbit, conjugated to horseradish peroxidase 
(Amersham Biosciences,Piscataway, NJ, USA). Immunostained bands were detected by 
chemiluminescent method (Pierce, Rockford, IL, USA). 
 
Transwell migration assay. 
Migration assay was performed using a 24-well plate with a non-coated 8-mm pore size filter in the 
insert chamber (Falcon). Cells were transfected with mirVana™ miRNA Mimic Negative Control 
#1 (Ambion) or hsa-miR-128-3p mirVana™ miRNA Mimic (Ambion), for miR-128-3p depletion 
we used mirVana™ miRNA Inhibitor Negative Control #1 or hsa-miR-128-3p mirVana™ miRNA 
Inhibitor (Ambion) at final concentration of 10nM. For Drosha depletion, we used 0.1uM siSCR or  
siDrosha and for rescue of Drosha, we cotransfected 500 ng of pcDNA3 (EV) or pcDNA3-
DROSHA expression plasmid and 5nM of hsa-miR-128-3p mirVana™ miRNA Mimic (Ambion). 
 After 48 or 72 hours from transfection, cells were resuspended in RPMI media without FBS and 
seeded into the insert chamber. Cells were allowed to migrate for 12 h into the bottom chamber 
containing 0,7 ml RPMI media containing 5% or 1% FBS in a humidified incubator at 37°C in 5% 
CO2. Migrated cells that attached to the outside of the filter were visualized by staining with DAPI 
and counted.  
 
Wound healing assay.  
H1299 and A459 cell lines transfected with mirVana™ miRNA Mimic Negative Control #1 
(Ambion) or hsa-miR-128-3p mirVana™ miRNA Mimic (Ambion) or with mirVana™ miRNA 
Inhibitor Negative Control #1 or hsa-miR-128-3p mirVana™ miRNA Inhibitor (Ambion), or with 
siSCR or siDrosha, were grown to 80% confluence in 6-well tissue culture plates and wounded with 
a sterile 200ul pipet tip to remove cells by perpendicular linear scrapes. PBS 1x washing was used 
to remove loosely attached cells. The cells were incubated in full medium with 10% FBS for 24 h. 
The progression of migration was photographed immediately, at 24 h after wounding. 
 
Scattering assays. 
For scattering assay 1000 cells were seeded in six-well plates and allowed to settle. After 96h 
H1299 cells were transfected with mirVana™ miRNA Mimic Negative Control #1 (Ambion) or 
hsa-miR-128-3p mirVana™ miRNA Mimic (Ambion). Following 48 h, it was captured phase-
contrast images of scattered cells. 
 
Immunofluorescence. 
For immunofluorescence assay cells were transfected with mirVana™ miRNA Mimic Negative 
Control #1 (Ambion) or hsa-miR-128-3p mirVana™ miRNA Mimic (Ambion) or with siSCR or 
siDrosha. 72h after transfection cells were washed twice with PBS 1% and then were fixed with 4% 
formaldehyde in PBS. After that cells were washed twice with PBS 1% and incubated for 5 min 
with 0.25% Triton and 5% BSA in PBS 1%. Then cells were washed with PBS 1% and incubated 
o.n. with rabbit monoclonal N-cad (Santa Cruz Biotechnology) 1:400 in 0.25% Triton and 1% BSA 
in PBS 1%.   The day after cells were washed three times with PBS 1% and followed by incubation 
with Alexa Flour 488 (rabbit) conjugated secondary antibodies (Molecular Probes Inc., Eugene, 
OR, USA) for 2 hours at RT. After washing three times with 0.02% Tween-20 and 1% BSA in PBS 
1%, the coverslips were counterstained with DAPI 5 min and mounted with Vectashield (Vector 
Labs,Burlingame, CA, USA). Cells were examined under a Zeiss LSM 510 laser scanning 
fluorescence confocal microscope (Zeiss, Wetzlar, Germany).  
 
EnSpire® cellular label-free platform. 
 H1299 cells were seeded in specially designed 384-well plate with highly precise optical sensors 
able to measure changes in light refraction resulting from dynamic mass redistribution (DMR) 
within the cell’s monolayer. Change in the light refraction was indicated by a shift in wavelength. 
 
Microarray data analysis. 
Arrays were verified for quality control and extracted by Agilent Feature Extraction 10.7.3.1 
software and entirely processed by MATLAB (The MathWorks Inc.) in house-built routines. All 
values lower than 1 were considered below detection and threshold to 1. The arrays were 
normalized by dividing by the mean intensity only using the 25th and 75th percentile range of the 
data, preventing large outliers from skewing the normalization. Data were log2-trasformed. 
Deregulated miRNAs were established by permutation test and a false discovery procedure (Storey, 
2002) used for multiple comparisons. Unsupervised hierarchical clustering was performed to 
individuate specific pattern of expression among samples and clusters of miRNAs. 
Significance was defined at the p<0.05 level. 
 In silico miRNA targets identification. 
Several prediction target tools were interrogated by using the web server tool MirWalk2 
(http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/). 
 
Bioinformatic analysis of TCGA dataset. 
As validation set we used TCGA lung adenocarcinoma (TCGA Research Network: 
http://cancergenome.nih.gov/."). MiRNA deregulation was assessed by paired or unpaired Student’s 
t-test. Significance was defined at the p<0.05 level. 
 
Kaplan–Meier analysis. 
For survival analysis of specific genes we used Kaplan-Meier plotter (http://kmplot.com/analysis/). 
Local recurrence-free survival (RFS) was evaluated by using Kaplan-Meier analysis and Cox 
proportional hazard regression model. Intensity levels of tumoral samples were z-score transformed 
and survival analysis was conducted by using those samples with absolute z-score higher than 0.5. 
The log-rank test was used to evaluate differences between curves. Significance was defined at the 
p<0.05 level.  
 
Results  
 
MiR-128-3p expression is up-regulated in NSCLC tissues. 
We have previously shown that miR-128-3p was a transcriptional target of gain of function mutant-
p53 proteins in lung cancer cells (20). To further investigate the oncogenic potential of miR-128-3p 
we evaluated the expression levels of miR-128-3p in a large lung adenocarcinoma patient cohort 
from The Cancer Genome Atlas (TCGA) database including data from XXX specimens. 
Interestingly, miR-128-3p resulted to be significantly up-regulated in 506 tumoral tissues when 
compared to 46 non-tumoral lung tissues (Figure 1A). This was independent of the tumor stage 
(Supplementary Figure S1). MiR-128-3p expression resulted to be significantly associated with 
TP53 status, exhibiting higher expression in tumor samples carrying TP53 mutations (Figure 1B). 
The analysis of recurrence-free survival of TCGA lung cancer patients showed a positive trend 
between high levels of miR-128-3p and probability of recurrence (Figure 1C). Altogether these data 
mirror an oncogenic role of miR-128-3p in lung cancer. 
 
MiR-128-3p expression triggers a global down-regulation of miRNAs. 
Commentato [u1]: Inserire numero 
The oncogenic properties of a miRNA may derive from altering miRNA homeostasis by targeting 
key processing enzymes. We explored whether such a mechanism may act in miR-128-3p-
expressing NSCLC cells. We found that ectopic expression of miR-128-3p caused a pronounced 
global down-regulation of miRNAs in both H1299 and A459 cells (Figure 2A-B, Supplementary 
Figure S2A-B and Supplementary Table S1-S2). In detail, in H1299 cells, 106 out of the 247 
expressed miRNAs were significantly down-regulated as compared to control cells (Figure 2A and 
Supplementary Figure S2A). Similarly, in A459 cells 151 out of the 254 expressed miRNAs were 
significantly down-regulated (Figure 2B and Supplementary Figure S2B). These findings accounted 
for a remarkable effect of miR-128-3p on global miRNAs expression. To support this observation, 
we analysed, by qRT-PCR, the expression levels of a set of representative miRNAs upon over-
expression or depletion of miR-128-3p in H1299 and A549 cells (Figure 2C and Supplementary 
Figure S2C-D). This confirmed a widespread miRNAs down-regulation induced by miR-128-3p 
which was released by depleting the latter, thus enforcing a strong correlation between the miR-
128-3p levels and those of multiple cognate miRNAs (Figure 2C and Supplementary Figure S2C-
D). Additionally, we observed an accumulation of primary miRNAs (pri-miRs) in miR-128-3p 
over-expressing cells, suggesting a specific effect of miR-128-3p on miRNAs maturation steps 
rather than on miRNAs transcription (Figure 2D).  
To rule out the possibility that the down-regulation of miRNAs observed could be ascribed to 
aspecific effects of the miR-128-3p agonist molecule, we transfected unrelated agonist molecules 
and we found this not to be the case (Figure 2E). 
Collectively these findings suggested that the oncogenic activity of miR-128-3p in lung cancer 
might occur through a widespread miRNAs down-regulation. 
 
The miRNA processing enzymes Drosha and Dicer are novel targets of miR-128-3p. 
The unexpected global effect on the miRNA levels in miR-128-3p-expressing cells prompted us to 
investigate whether this may happen through targeting of miRNA processing factors. Intriguingly, 
in silico analysis revealed that, among the putative targets of miR-128-3p, Drosha (RNASEN) and 
Dicer were scoring high.  
In agreement with the mentioned altered expression of Drosha and Dicer in many unrelated tumors   
and with their prognostic value (10-12), we found a significant positive correlation between high 
levels of Drosha and Dicer and overall survival in a cohort of 720 patients affected by lung 
adenocarcinoma (Figure 3A-B). 
To assess if miR-128-3p was effectively able to bind Drosha and Dicer 3’UTRs, we used luciferase 
reporter constructs with the full-length 3'UTR of Drosha or Dicer, wild-type or mutated in miR-
128-3p-binding sites (Figure 3C). The activity of these reporters was evaluated in H1299 cells 
transiently transfected with miR-128-3p mimic or control mimic. As shown in Figure 3c, miR-128-
3p significantly reduced the relative luciferase activity of the wild-type reporters but not that of 
mutant reporters. 
Next, we evaluated the protein expression levels of Drosha and Dicer in NSCLC cell lines 
transiently transfected with the miR-128-3p agonist, and in H1299 cells depleted for miR-128-3p by 
means of an inhibitor molecule or a decoy vector (Figure 3D and Supplementary Figure S3). As 
shown in Figure 3D and in Supplementary Figure S2B, miR-128-3p ectopic expression reduced the 
protein levels of Drosha and Dicer, and, conversely, its depletion determined increased Drosha and 
Dicer protein levels. 
These findings indicated a direct inhibitory effect of miR-128-3p on Drosha and Dicer expression. 
Moreover, Drosha or Dicer depletion in H1299 cells mimicked the effect of increasing the miR-
128-3p on mature miRNAs expression (Figure 3E-F). This strongly supported that miR-128-3p-
mediated down-regulation of miRNAs was a consequence of its inhibitory effect on Drosha and 
Dicer translation. 
 
Ectopic expression of miR-128-3p promotes migratory phenotype in lung cancer cells. 
To assess the functional relevance of the observed phenomena, we performed functional assays in 
NSCLC cells transfected with a miR-128-3p mimic, miR-128-3p inhibitor or decoy vector.  
Firstly, we did not witness effects of miR-128-3p expression on clonogenicity or cell cycle 
progression (Supplementary Figure S4A-D).  
On the other hand, by performing both trans-well and wound-healing migration assays in H1299 
and A459 cells, we found that miR-128-3p-expressing cells were hypermigratory (Figure 4A-B and 
Supplementary Figure S5A-C). Conversely, miR-128-3p depletion strongly discouraged the 
migration of H1299 cells (Figure 4A-B and Supplementary Figure S5D). 
Moreover, in NSCLC cells expressing ectopic miR-128-3p, we observed a striking change in cell 
morphology, consisting of a shift from a cobblestone shape, typical of epithelial phenotype, into a 
spindle-fibroblast-like morphology, with extensive cellular scattering (Figure 4C and 
Supplementary Figure S5E). Such a changes were quantitatively addressed by means of label-free 
assays and were not due to any alteration in cells viability (Figure 4D and Supplementary Figure 
S5F). Morphological changes were not detectable in H1299 cells depleted for miR-128-3p 
(Supplementary Figure S5G-H). 
 
MiR-128-3p-mediated miRNAs down-regulation promotes EMT program. 
EMT is an early and key step in the metastatic cascade in which epithelial cells acquire the motile 
and invasive characteristics of mesenchymal cells through a process involving cytoskeleton 
remodelling and cell morphologic changes (21). The observed morphological changes in NSCLC 
cells expressing ectopic miR-128-3p prompted us to study whether the molecular alterations typical 
of the EMT occurred in miR-128-expressing cells and could explain the effects of such a miRNA 
on cell migration. 
Firstly, we found that the expression levels of two key transcription factors, SNAIL and ZEB1 (21) 
were significantly increased in H1299 cells upon miR-128-3p over-expression (Figure 5A). On the 
contrary, miR-128-3p depletion in H1299 cells determined a significant reduction of both SNAIL 
and ZEB1 mRNA and protein levels (Figure 5A). Moreover, we observed that miR-128-3p 
expression in H1299 cells determined a significant increase in the membrane localization of N-
Cadherin protein, a typical feature of mesenchymal cells (Figure 5B and Supplementary Figure S6). 
As a further readout of the up-regulation of SNAIL and ZEB1 by miR-128-3p we observed 
increased mRNA levels of MMP9, a final effectors of the EMT-associated invasive phenotype 
(Figure  5C). 
To explain the induction of SNAIL and ZEB1 expression by miR-128-3p, we analyzed the 
expression levels of a set of miRNAs previously reported to target SNAIL (miR-30b, miR-30e, 
miR-137) and ZEB1 (miR-96, miR-130b, miR-192) (22-24). As shown in Figure 5D, upon miR-
128-3p ectopic expression, there was a significant decrease in the expression levels of all of the 
anti-EMT miRNAs that inversely correlated with SNAIL and ZEB1 induction.  
In support of a key role for miR-128-3p in determining metastatic potential of lung cancer cells, we 
also had an in vivo evidence: in a casuistry of 13 primitive lung cancer tissues and their matched 
brain metastasis, that we previously profiled for miRNAs expression, we observed a significant up-
regulation of miR-128-3p in brain metastases compared to primary lesions (Fig 5E) (25). 
All these findings indicated that miR-128-3p-mediated tumorigenic phenotype of lung cancer cells 
was in part sustained by Drosha and Dicer depletion and consequently by global miRNAs 
inhibition. In particular, miR-128-3p promoted epithelial plasticity through the regulation of 
mesenchymal genes expression, in part by inhibiting anti-EMT miRNAs. 
 
Drosha depletion in lung cancer cells mimics miR-128-3p effects on cell migration and EMT. 
Due to the established direct effect of miR-128-3p on Drosha and Dicer expression and 
consequently on global miRNAs expression, that in part promote a migratory phenotype, we further 
investigated the possible implication of Drosha and Dicer depletion in lung cancer cell migration 
and EMT promotion. 
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By performing migration assays in lung cancer cells depleted for Drosha or Dicer we observed a 
significant effect, at similar extent of miR-128-3p over-expression, only with Drosha silencing 
rather than Dicer depletion (Figure 6A-B and Supplementary Figure S7A-B). These data indicated 
an implication only for Drosha, rather than Dicer, in miR-128-3p-mediated migratory phenotype. In 
support of these results, ectopic expression of Drosha in miR-128-3p-expressing H1299 cells 
rescued the migratory phenotype (Figure 6C). 
Looking at changes in cell morphology, in support to a mesenchymal phenotype, we observed a 
significant effect in H1299 cells depleted for Drosha (Figure 6D). Such a changes were 
quantitatively addressed by means of label-free assays and were not due to any alteration in cells 
viability (Figure 6D and Supplementary Figure S7C). Moreover, these morphological changes were 
rescued in miR-128-3p-expressing H1299 cells upon ectopic expression of Drosha (Figure 6E and 
Supplementary Figure S7D). All these data suggested an implication of Drosha in miR-128-3p-
mediated EMT.  
To deeper investigate Drosha involvement in EMT we looked at the same EMT effectors modulated 
by miR-128-3p.  In particular, in H1299 cells upon Drosha depletion, we observed a localization of 
N-cadherin in membrane and an increase in its protein levels (Supplementary Figure S7E). 
Moreover, Drosha depletion determined an increase in SNAIL and ZEB1 protein levels 
concomitantly with a reduction in the expression of miRNAs targeting SNAIL or ZEB1 (Figure 6F-
G). As showed for miR-128-3p, the final readout of EMT promotion by Drosha depletion was in 
part represented by the increase in MMP9 transcriptional levels (Supplementary Figure S7F). 
 
Discussion 
 
This study provides the first evidence for the ability of a single miRNA, miR-128-3p, to modulate, 
concurrently, the expression of two major players of miRNAs biosynthesis, Drosha and Dicer. This 
elicited a global miRNAs down-regulation that conferred a more aggressive tumoral phenotype to 
lung cancer cells.  
Drosha and Dicer down-regulation is a widespread phenomenon in cancer and it is closely 
correlated to poor patients outcome (7,10,26-28). Notably, Karube and colleagues found that down-
regulation of Dicer expression correlated with decreased post-operative survival in lung cancer 
patients (12). Moreover, Drosha and Dicer have been demonstrated to be positive prognostic factors 
in NSCLC patients with normal performance status (11). In agreement with these evidences, we 
observed , by means of an on-line survival analysis software, a significant positive correlation 
between high levels of Drosha and Dicer and overall survival in a cohort of 720 patients affected by 
lung adenocarcinoma (29). 
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Understanding the molecular processes that determined Drosha or Dicer depletion in cancer is an 
emerging open field, due to their deep impact on global miRNAs expression. Despite some 
evidence for the occurrence of specific somatic mutations in Drosha and Dicer genes as 
determinants of their down-regulation in cancer (15,27,30,31), a post-transcriptional regulatory 
mechanism mediated by miRNAs that directly impinges on Dicer expression has been proposed 
(16-18,32). In detail, Martello et al., identified miR-103 and miR-107 as negative regulators of 
Dicer that consequently determined a global miRNAs down-regulation, promoting a higher 
metastatic potential of breast cancer cells (16). FurthermoreMoreover, Dicer has been reported to be 
a direct target of miR-630 and let-7 (17,18). More recently Sha et al., demonstrated that miR-18a 
upregulation decreases Dicer at mRNA and protein levels and conferred paclitaxel resistance in 
triple negative breast cancer (32). Till now, nothing was known about miRNAs-mediated regulation 
of Drosha.  
Here we showed that miR-128-3p up-regulation is functionally relevant, in that it elicited a global 
miRNA down-regulation mediated by direct inhibitory effect on both Drosha and Dicer 3’UTRs.  
It is well established that global down-regulation of miRNAs expression, caused by depletion of 
Drosha and Dicer, is a key determinant of the tumoral phenotype and it was observed in different 
cancers (6,7,16,26). For example, Chen and collaborators demonstrated that Dicer depletion in 
NSCLC cells, and the consequent global miRNA down-regulation, mainly impinged on tumor 
angiogenesis (6). Martello et al., reported that in breast cancer, miRNAs down-regulation, 
determined by Dicer depletion, mainly affected EMT driven metastatic pathways (16). It is evident 
that not all the pathways involved in tumorigenesis are affected by such a global miRNAs down-
regulation at similar extent, probably for the occurrence of a sort of balance between antagonist 
miRNAs. 
In our proposed model, up-regulation of the miR-128-3p could initiate a signaling cascade that 
leads to global miRNAs down-regulation and consequently to acquisition of pro-tumorigenic 
properties (Figure 7). In such a context, and in strict agreement with our previous observations, we 
found that Drosha depletion by siRNA mimicked the effects of miR-128-3p overexpression 
suggesting, again, a close correlation between the miR-128-3p mediated miRNAs down-regulation 
and the impact on cell motility. In particular, Drosha depletion seemed to be implicated in the 
promotion of a migratory phenotype in NSCLC.    
In a previous study Hu J. et al, demonstrated a tumor suppressor activity of miR-128 gene in 
NSCLC cells (33). In particular they evaluated the functional effects of miR-128 precursor, by 
using a construct encoding for both miR-128-3p and its complementary miR (ref). On a different 
note, by using a specific mimic molecule, we exclusively evaluated the activity of  mature miR-
Commentato [u4]:  
128-3p, whose effect on the motility of NSCLC were unprecedented.  
We have previously demonstrated that miR-128-3p was a transcriptional target of the oncogenic 
mutant-p53 protein, and that its expression contributed to mutant-p53 gain of function through the 
promotion of chemoresistance in lung cancer (20). Additionally, in agreement with our previously 
reported data, we observed a significant correlation between miR-128-3p expression and TP53 
mutations in lung cancer. By analysing miR-128-3p expression levels in lung cancer data sets from 
the TCGA consortium, we observed an up-regulation of miR-128-3p in tumor samples as compared 
to normal tissues was independent of the tumor stage. Here we speculate that keeping high levels of 
miR-128-3p might represent a cancer-specific adaptive mechanism to hijack the canonical miRNA 
biogenesis pathway, thereby leading to alternative mechanisms that generate functional oncogenic 
miRNAs (34-38). More recently, it has been demonstrated that intronic miRNAs can be processed 
by splicing enzymes avoiding Drosha and Dicer cleavage (34-38). It is possible that miR-128-3p, 
being located into ARPP-21 gene, is involved in this kind of mechanism. 
 
This study further confirms how global miRNA down-regulation could be considered a hallmark of 
aggressive cancers. The identification of an oncogenic miRNA, such as miR-128-3p, that impinges 
simultaneously on the two major drivers of miRNAs biosynthesis, might pave the way for the 
development of novel targeted therapeutic strategies for lung cancer, especially for those patients 
exhibiting a global miRNAs down-regulation. 
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FIGURE LEGENDS 
 
Figure 1. MiR-128-3p expression in lung cancer casuistry.  
A. MiR-128-3p expression levels distribution in normal lung tissues (N) and lung cancer samples 
(T) from TCGA casuistry. B. MiR-128-3p expression levels distribution accordingly to p53 protein 
status, wild type (wt) or mutant (mutP53), of  lung cancer samples (T) and normal tissues (N) from 
TCGA casuistry. C. Kaplan-Meier curve of recurrence-free survival for lung adenocarcinoma 
patients from TCGA casuistry with miR-128-3p high (Z score >0.5; n=121) and miR-128-3p low (Z 
score <-0.5 ; n=128) expression.  
 
Figure 2. Oncogenic miR-128-3p induces a global down-regulation of mature miRNAs in lung 
cancer cells. 
A-B. Volcano plot of significance against the relative expression differences between the control- or 
miR-128-3p-mimics treated groups in H1299 (A) and A459 (B) lung cancer cells. Each dot 
represents one miRNAs that was filtered and had detectable expression upon miR-128-3p 
expression. The X-axis displays log2-transformed signal intensity differences between the control 
group and the miR-128-3p group; the Y-axis represents calculated p-values of statistical differences 
between control and treated distributions. MiRNAs positioned in the left and right upper-lateral 
quadrants above red dot line represent significant down-regulation (↓) and up-regulation (↑), 
respectively. C. Heat Map relative to qRT-PCR analysis of 5 representative miRNAs of the 
identified signature (miR-16, miR-17, miR-28, miR-30a-3p miR-423) in three independent 
preparations of H1299 cells transiently transfected with miR-128-3p mimic or miR-128-3p inhibitor 
(p-value<0.05). D. qRT-PCR analysis of 5 representative primary miRNA (pri-miRs) used for array 
validation, in H1299 cells upon miR-128-3p expression. E. qRT-PCR analysis of 4 representative 
miRNAs of the identified signature (miR-16a, miR-26a, miR-17-5p, miR-106a) in H1299 cells 
transiently transfected with miR-128-3p, or miR-10b*,or miR-139-5p, or let-7c, or miR-98, or miR-
34b, or miR-34c mimic molecules (miR-x). Histograms show the mean of three experiments. 
 
Figure 3. MiR-128-3p targets the components of the miRNAs processing. 
A. Kaplan-Meier curve of overall survival for lung adenocarcinoma patients with Drosha high 
(n=359) and Drosha low (n=361) expression. B. Kaplan-Meier curve of overall survival for lung 
adenocarcinoma patients with Dicer high (n=360) and Dicer low (n=360) expression. C. Schematic 
representation of plasmids used in luciferase experiments (upper panel) and firefly luciferase 
activity of Drosha-3’UTR-WT, Drosha-3’UTR-MUT, Dicer-3’UTR-WT and Dicer-3’UTR-MUT 
reporter genes in H1299 cells transiently transfected with miR-128-3p mimic or control mimic 
(lower panel). Results are presented as Firefly activity relative to total proteins and Renilla activity. 
Histograms show the mean of three experiments performed in duplicate. D. Western-blot analysis 
of Drosha and Dicer proteins expression levels in H1299 cells upon miR-128-3p over-expression 
and in H1299 cells depleted for miR-128-3p using miR-128-3p-inhibitor or miR-128-3p decoy 
vector. E-F. qRT-PCR analysis of the expression levels of a set of identified miRNAs in H1299 
depleted for DROSHA (E) or DICER (F).  
*p-value<0.05; **p value<0.01, ***p-value<0.001.  
 
Figure 4. MiR-128-3p promotes lung cancer cells motility. 
A. Transwell migration assay in H1299 cells transiently transfected with miR-128-3p mimic or 
miR-128-3p inhibitor. Fold increase in cell migration is represented by the histogram. B. Wound 
healing assays in H1299 cells transiently transfected with miR-128-3p mimic or miR-128-3p 
inhibitor. The histogram represents folds of wound width relative to control. C. Phase-contrast 
microscopy images (magnification x5) of cell scattering assay in H1299 cells transfected with miR-
128-3p mimic or control mimic. D. Label-free assays in H1299 transiently transfected with miR-
128-3p mimic or control mimic at the indicate time points. The change in impedance of H1299 cells 
is represented by the graph (left panel). The right panel shows phase-contrast microscopy images 
(magnification x10) showing H1299 cells morphology after 72h from miR-128-3p mimic or control 
mimic transfection.  
*p-value < 0.05; **p-value<0.01; ***p-value<0.001. 
 
Figure 5. MiR-128-3p promotes EMT by miRNAs down-regulation. 
A. qRT-PCR analysis (upper panel) and western-blot analysis (lower panel) of SNAIL and ZEB1 
levels in H1299 cells transiently transfected with miR-128-3p mimic or miR-128-3p inhibitor. B. 
Graph representation of immunofluorescence assay for N-Cadherin protein in H1299 cells 
transiently transfected with miR-128-3p mimic or control mimic. C. qRT-PCR analysis of MMP9 
expression levels H1299 cells transiently transfected with miR-128-3p mimic or control mimic. D. 
qRT-PCR analysis of the expression levels of miRNAs targeting SNAIL or ZEB1 3’UTR, in H1299 
cells upon miR-128-3p over-expression. E. MiR-128-3p expression levels in 13 brain metastasis 
(BM) versus 13 matched primary lung cancer (PLC) using Agilent microarray platform.  
*pvalue<0.05; **p-value<0.01; ***p-value<0.001. 
 
 
Figure 6. Drosha counteracts miR-128-3p functional effects. 
A. Transwell migration assay in H1299 cells depleted for Drosha. Protein levels of Drosha were 
analyzed by western-blot analysis (lower panel). Fold increase in cell migration is represented by 
the histogram (upper panel). B. Wound healing assays in H1299 cells depleted for Drosha. The 
histogram represents folds of wound width relative to control. C. Transwell migration assay in 
H1299 cells transiently transfected either with an empty vector (EV) or a DROSHA expression 
vector and miR-128-3p mimic or control mimic. Fold increase in cell migration is represented by 
the histogram.**: pvalue<0.01 vs control+EV ‡: pvalue<0.05 vs miR-128-3p+DROSHA. D. Label-
free assays in H1299 depleted for Drosha at the indicate time points. The change in impedance of 
H1299 cells is represented by the graph (right panel). The left panel shows phase-contrast 
microscopy images (magnification x10) showing H1299 cells morphology upon silencing of Drosha 
or relative control (siSCR) after 72h from transfection. E. Label-free assays in H1299 cells 
transiently transfected either with an empty vector (EV) or a DROSHA expression vector and miR-
128-3p mimic or control mimic at the indicate time points. The change in impedance of H1299 cells 
is represented by the graph (right panel). The left panel shows phase-contrast microscopy images 
(magnification x10) showing H1299 cells morphology after 48h from transfection. *: pvalue<0.05, 
**: pvalue<0.01 vs control+EV ‡: pvalue<0.05 vs miR-128-3p+DROSHA. ‡ ‡: pvalue<0.01 vs 
miR-128-3p+DROSHA. F. Western-blot analysis of SNAIL and ZEB1 levels in H1299 cells 
depleted for Drosha. G. qRT-PCR analysis of the expression levels of miRNAs targeting SNAIL or 
ZEB1 3’UTR, in H1299 cells depleted for Drosha.  
*pvalue<0.05; **p-value<0.01; ***p-value<0.001. 
 
Figure 7. Schematic representation of the proposed molecular mechanism 
In lung cancer cells, the oncogenic miR-128-3p directly binds to Drosha and Dicer 3’UTR 
determining the inhibition of their expression. The consequence is a significant alteration in 
miRNAs biogenesis, characterized by a global down-regulation in miRNAs expression, a feature 
known to promote tumorigenesis. Among the down-regulated miRNAs by miR-128-3p, there are a 
group of miRNAs that target SNAIL and ZEB1, two of the major players of EMT. This event leads 
to an up-regulation of SNAIL and ZEB1 and to a consequent induction of EMT that promotes 
metastatic potential of lung cancer cells. MiR-128-3p levels are kept high probably by alternative 
processing mechanisms that are Drosha/Dicer-independent. 
 
 
